These data indicate that downregulation of CERT and the subsequent disruption of the SM/ceramide balance were, at least in part, responsible for anti-cancer effects of SphK2 deficiency in NAFLD-HCC. This evidence concerns the gene SPHK2 and metabolic dysfunction-associated steatotic liver disease.